Transcatheter aortic valve replacement is a safe and effective alternative to surgery in patients with severe aortic stenosis and high surgical risk as the 5-year results of PARTNER 1 Alternate showed. The aim of this study was to evaluate the result of the Edwards Sapien 3 valve in patients with severe aortic stenosis and intermediate<a href="https://solaci.org/en/2015/06/24/sapiens-3-favorable-outcomes-with-tavi-in-intermediate-risk-patients/" title="Read more" >...</a>

The CoreValve ADVANCE II Trial is a research study of the best practices to implement this device. Those practices included a careful assessment using scan to choose the right valve size, control the depth of the implant to 6 mm or less in relation to the valve annulus and adherence to international standards for pacemaker<a href="https://solaci.org/en/2015/06/24/advance-ii-corevalve-trial-results-at-six-months-of-self-expanding-aortic-valve/" title="Read more" >...</a>

This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30<a href="https://solaci.org/en/2015/06/24/corevalve-evolut-r-ce-good-results-at-6-months-of-the-new-corevalve-repositionable/" title="Read more" >...</a>

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used<a href="https://solaci.org/en/2015/06/24/notion-tavr-in-low-risk-patients/" title="Read more" >...</a>

Single chamber pacemaker implantation leads to a desynchronization of ventricular depolarization. This study aims to evaluate the implant of biventricular versus univentricular pacemaker. 902 patients were included in the group with biventricular pacemaker and 908 in the univentricular pacing group. The primary objective was to evaluate the long-term mortality and needs hospitalization for heart failure.<a href="https://solaci.org/en/2015/06/24/biopace-study-biventricular-pacing-to-prevent-cardiac-desynchronization/" title="Read more" >...</a>

Direct Flow Medical prosthesis is a nonmetallic, repositionable, recaptured valve (even after posts dilate), that does not require a pacemakers use during both implantation and post-dilatation.&nbsp; The aim of this study was to evaluate new valve results to one year in patients with symptomatic severe aortic stenosis with 19 and 26 mm ring, EuroScore of<a href="https://solaci.org/en/2015/06/24/discover-trial-results-at-one-year-of-the-new-nonmetallic-percutaneous-aortic-valve/" title="Read more" >...</a>

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE &gt; 18.5<a href="https://solaci.org/en/2015/06/24/uk-tavi-registry-long-term-results-of-tavi-in-the-uk/" title="Read more" >...</a>